Steroid-induced diabetes: A clinical and molecular approach to understanding and treatment

Diabetes/Metabolism Research and Reviews

Volumn 30, Issue 2, 2014, Pages 96-102

  Hwang, Jessica L ^a   Weiss, Roy E ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Glucocorticoids; Insulin resistance; New onset diabetes after transplant; Steroid induced diabetes

Indexed keywords

CALCINEURIN INHIBITOR; CORTICOTROPIN RELEASING FACTOR; DEXAMETHASONE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOCORTICOID; GLUCOSE; GLUCOSE TRANSPORTER 4; GLYCEROPHOSPHATE; GLYCOGEN; HYDROCORTISONE; IMMUNOSUPPRESSIVE AGENT; INCRETIN; INSULIN; METFORMIN; PREDNISOLONE; PREDNISONE; SULFONYLUREA;

AGE; BINDING AFFINITY; BLOOD GLUCOSE MONITORING; BODY MASS; CARBOHYDRATE SYNTHESIS; CELL DEATH; CELL FUNCTION; COMORBIDITY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE COURSE; DISEASE PREDISPOSITION; DRUG INDUCED DISEASE; EARLY DIAGNOSIS; ENDOPLASMIC RETICULUM; FAMILY HISTORY; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLYCEMIC CONTROL; GLYCERONEOGENESIS; GLYCOGEN SYNTHESIS; GRAFT FAILURE; HEPATITIS C; HOMEOSTASIS; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERGLYCEMIA; HYPOMAGNESEMIA; IMMUNOSUPPRESSIVE TREATMENT; IMPAIRED GLUCOSE TOLERANCE; IN VITRO STUDY; INSULIN BINDING; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; META ANALYSIS (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS FUNCTION; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; SKELETAL MUSCLE; STEROID INDUCED DIABETES MELLITUS; TREATMENT DURATION;

GLUCOCORTICOIDS; INSULIN RESISTANCE; NEW ONSET DIABETES AFTER TRANSPLANT; STEROID-INDUCED DIABETES;

ADIPOSE TISSUE; CARBOHYDRATE METABOLISM; CONGRESSES AS TOPIC; DIABETES MELLITUS; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIPID METABOLISM; LIVER; MODELS, BIOLOGICAL; RISK FACTORS; STEROIDS;

EID: 84893446310     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2486     Document Type: Review

References (40)

1. Conn JW, Fajans SS. Influence of adrenal cortical steroids on carbohydrate metabolism in man. Metabolism 1956; 5: 114-127.
2. Diagnosis and classification of diabetes mellitus. Diabetes Care 2012; 35(Suppl 1): S64-71.
3. Donihi AC, Raval D, Saul M, Korytkowski MT, DeVita MA. Prevalence and predictors of corticosteroid-related hyperglycemia in hospitalized patients. Endocr Pract 2006; 12: 358-362.
4. Gurwitz JH, Bohn RL, Glynn RJ, Monane M, Mogun H, Avorn J. Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med 1994; 154: 97-101.
5. Starzl TE. Experience in Renal Transplantation. Saunders: Philadelphia, 1964.
6. Balla A, Chobanian M. New-onset diabetes after transplantation: a review of recent literature. Curr Opin Organ Transplant 2009; 14: 375-379.
7. Anderson AL, Lewis DA, Steinke DT, Ranjan D, Smith KM, Clifford TM. Effects of hyperglycemia on the development of new-onset diabetes after liver transplantation. Prog Transplant 2009; 19: 298-303.
8. Belle-van Meerkerk G, van de Graaf EA, Kwakkel-van Erp JM, et al. Diabetes before and after lung transplantation in patients with cystic fibrosis and other lung diseases. Diabet Med 2012; 29: e159-162.
9. Depczynski B, Daly B, Campbell LV, Chisholm DJ, Keogh A. Predicting the occurrence of diabetes mellitus in recipients of heart transplants. Diabet Med 2000; 17: 15-19.
10. Yates CJ, Fourlanos S, Hjelmesaeth J, Colman PG, Cohney SJ. New-onset diabetes after kidney transplantation-changes and challenges. Am J Transplant 2012; 12: 820-828.
11. Ha Y, Lee KH, Jung S, Lee SW, Lee SK, Park YB. Glucocorticoid-induced diabetes mellitus in patients with systemic lupus erythematosus treated with high-dose glucocorticoid therapy. Lupus 2011; 20: 1027-1034.
12. Papang R, John AS, Abraham S, Rao PS. A study of steroid-induced diabetes mellitus in leprosy. Indian J Lepr 2009; 81: 125-129.
13. Mazziotti G, Gazzaruso C, Giustina A. Diabetes in Cushing syndrome: basic and clinical aspects. Trends Endocrinol Metab 2011; 22: 499-506.
14. van Raalte DH, Nofrate V, Bunck MC, et al. Acute and 2-week exposure to prednisolone impair different aspects of beta-cell function in healthy men. Eur J Endocrinol 2010; 162: 729-735.
15. Yasuda K, Hines E 3rd, Kitabchi AE. Hypercortisolism and insulin resistance: comparative effects of prednisone, hydrocortisone, and dexamethasone on insulin binding of human erythrocytes. J Clin Endocrinol Metab 1982; 55: 910-915.
16. Plat L, Byrne MM, Sturis J, et al. Effects of morning cortisol elevation on insulin secretion and glucose regulation in humans. Am J Physiol 1996; 270: E36-42.
17. Linssen MM, van Raalte DH, Toonen EJ, et al. Prednisolone-induced beta cell dysfunction is associated with impaired endoplasmic reticulum homeostasis in INS-1E cells. Cell Signal 2011; 23: 1708-1715.
18. Cadoudal T, Leroyer S, Reis AF, et al. Proposed involvement of adipocyte glyceroneogenesis and phosphoenolpyruvate carboxykinase in the metabolic syndrome. Biochimie 2005; 87: 27-32.
19. Franckhauser S, Antras-Ferry J, Robin P, Robin D, Granner DK, Forest C. Expression of the phosphoenolpyruvate carboxykinase gene in 3T3-F442A adipose cells: opposite effects of dexamethasone and isoprenaline on transcription. Biochem J 1995; 305(Pt 1): 65-71.
20. Cadoudal T, Blouin JM, Collinet M, et al. Acute and selective regulation of glyceroneogenesis and cytosolic phosphoenolpyruvate carboxykinase in adipose tissue by thiazolidinediones in type 2 diabetes. Diabetologia 2007; 50: 666-675.
21. van Raalte DH, Ouwens DM, Diamant M. Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options? Eur J Clin Invest 2009; 39: 81-93.
22. Weinstein SP, Wilson CM, Pritsker A, Cushman SW. Dexamethasone inhibits insulin-stimulated recruitment of GLUT4 to the cell surface in rat skeletal muscle. Metabolism 1998; 47: 3-6.
23. Kim SY, Yoo CG, Lee CT, et al. Incidence and risk factors of steroid-induced diabetes in patients with respiratory disease. J Korean Med Sci 2011; 26: 264-267.
24. Simmons LR, Molyneaux L, Yue DK, Chua EL. Steroid-induced diabetes: is it just unmasking of type 2 diabetes? ISRN Endocrinol 2012; 2012: 910905.
25. Mazzantini M, Torre C, Miccoli M, et al. Adverse events during longterm low-dose glucocorticoid treatment of polymyalgia rheumatica a retrospective study. J Rheumatol 2012; 39: 552-557.
26. Van Laecke S, Van Biesen W, Verbeke F, De Bacquer D, Peeters P, Vanholder R. Posttransplantation hypomagnesemia and its relation with immunosuppression as predictors of new-onset diabetes after transplantation. Am J Transplant 2009; 9: 2140-2149.
27. Baid S, Cosimi AB, Farrell ML, et al. Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Transplantation 2001; 72: 1066-1072.
28. Bahtiyar G, Shin JJ, Aytaman A, Sowers JR, McFarlane SI. Association of diabetes and hepatitis C infection: epidemiologic evidence and pathophysiologic insights. Curr Diab Rep 2004; 4: 194-198.
29. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Kanwal F, Dulai G. Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation: meta-analysis of clinical studies. Am J Transplant 2005; 5: 2433-2440.
30. Baldwin D, Apel J. Management of hyperglycemia in hospitalized patients with renal insufficiency or steroid-induced diabetes. Curr Diab Rep 2013; 13(1): 114-120.
31. Oyer DS, Shah A, Bettenhausen S. How to manage steroid diabetes in the patient with cancer. J Support Oncol 2006; 4: 479-483.
32. Clore JN, Thurby-Hay L. Glucocorticoid-induced hyperglycemia. Endocr Pract 2009; 15: 469-474.
33. Burt MG, Roberts GW, Aguilar-Loza NR, Frith P, Stranks SN. Continuous monitoring of circadian glycemic patterns in patients receiving prednisolone for COPD. J Clin Endocrinol Metab 2011; 96: 1789-1796.
34. Nam JH, Mun JI, Kim SI, et al. Beta-cell dysfunction rather than insulin resistance is the main contributing factor for the development of postrenal transplantation diabetes mellitus. Transplantation 2001; 71: 1417-1423.
35. Valderhaug TG, Jenssen T, Hartmann A, et al. Fasting plasma glucose and glycosylated hemoglobin in the screening for diabetes mellitus after renal transplantation. Transplantation 2009; 88: 429-434.
36. Guerra G, Ilahe A, Ciancio G. Diabetes and kidney transplantation: past, present, and future. Curr Diab Rep 2012; 12: 597-603.
37. Hjelmesaeth J, Hartmann A, Leivestad T, et al. The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events. Kidney Int 2006; 69: 588-595.
38. Oyer DS, Shah A, Bettenhausen S. How to manage steroid diabetes in the patient with cancer. J Support Oncol 2006; 4(9): 479-482.
39. Zhao R, Fuentes-Mattei E, Velazquez-Torres G, et al. Exenatide improves glucocorticoid-induced glucose intolerance in mice. Diabetes Metab Syndr Obes 2011; 4: 61-65.
40. van Raalte DH, van Genugten RE, Linssen MM, Ouwens DM, Diamant M. Glucagon-like peptide-1 receptor agonist treatment prevents glucocorticoid-induced glucose intolerance and islet-cell dysfunction in humans. Diabetes Care 2011; 34: 412-417.